AHA 2020 | Rise in Early Discharge After TAVR Has the Expected Cost

As hospitalization time after a transcatheter aortic valve replacement (TAVR) is reduced, we are observing a concomitant increase in re-hospitalizations due to conduction disorders. Early discharge is a great step, but it should be noted that conduction disorders can happen beyond 48 hours.

A few years ago, pacemaker implantation rates after discharge were about 7%; nowadays, that figure has almost been doubled.

Conduction system injury and its subsequent complete atrioventricular block is a well-known TAVR complication, whose prevalence rate varies according to prosthesis type, implantation technique, operator and center experience, etc. The worldwide trend to speed up patient discharge after TAVR has led to more indications for permanent pacemakers after the index hospitalization.

This paper, presented at the American Heart Association (AHA) 2020 Scientific Sessions and simultaneously published in JACC: Cardiovascular Interventions, describes this new reality.


Read also: AHA 2020 | POLYPILL: One Pill Plus Aspirin to Treat Everything.


The analysis included 62,083 patients registered in the United States database who underwent TAVR between 2012 and 2017. Out of all patients, 11% needed a permanent pacemaker after the procedure (most during the index hospitalization). During the study period, implantation rates were stable (p = 0.632 for trend).

Hospitalization time was significantly shortened from a mean 6 days in 2012 to just 2 days in 2017 (p < 0.0001).


Read also: The Most Read Scientific Articles in Interventional Cardiology.


The combination of shorter hospital stays and stable pacemaker rates means many patients underwent implantation in subsequent post-discharge visits.

Patients who present a high risk of atrioventricular block after discharge, those with right-sided bundle branch block, transient blockages after the procedure, a deep implant, or an oversized valve compared with annular dimensions should be considered for remote and continuous ambulatory monitoring.

mcp-y-tavi

Original title: Shifting trends in timing of pacemaker implantation after transcatheter aortic valve replacement.

Reference: Mazzella AJ et al. Presentado en el congreso AHA 2020 y publicado simultáneamente en J Am Coll Cardiol Intv. 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....